Peregrine Pharmaceuticals, Inc. to Present at Roth Capital Partners OC Growth Stock Conference

TUSTIN, CA--(Marketwire - March 10, 2011) -

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced it will present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference in Laguna Niguel, California on Monday, March 14, 2011 at 2:00 p.m. Pacific Time (5:00 p.m. ET).

Peregrine’s presentation will be webcast live and available for replay at: http://ir.peregrineinc.com/events.cfm

For more information about this conference, please visit: http://www.roth.com/main/page.aspx?PageID=7236

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: ROTH Capital Conference